Vasilip - Instructions For Use, Price, Reviews, Analogs Of Tablets

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Vasilip

Vasilip: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. In case of impaired renal function
12. 12. For violations of liver function
13. 13. Use in the elderly
14. 14. Drug interactions
15. 15. Analogs
16. 16. Terms and conditions of storage
17. 17. Terms of dispensing from pharmacies
18. 18. Reviews
19. 19. Price in pharmacies

Latin name: Vasilip

ATX code: C10AA01

Active ingredient: simvastatin (simvastatin)

Manufacturer: KRKA (Slovenia), KRKA-RUS (Russia)

Description and photo update: 2019-02-09

Prices in pharmacies: from 128 rubles.

Buy

Vasilip is a drug used to lower total cholesterol and low density lipoprotein (LDL) cholesterol in blood plasma.

Release form and composition

The drug is produced in the form of film-coated tablets: round, slightly biconvex with beveled edges, white or almost white (7 pieces in blisters, in a cardboard box 2 or 4 blisters and instructions for using Vazilip).

1 tablet contains 10 mg, 20 mg or 40 mg of the active substance - simvastatin.

Auxiliary components: butylhydroxyanisole, lactose monohydrate, microcrystalline cellulose, pregelatinized starch, anhydrous citric acid, ascorbic acid, corn starch, magnesium stearate.

The composition of the film shell: hypromellose, propylene glycol, talc, titanium dioxide.

Pharmacological properties

Pharmacodynamics

Simvastatin - the active substance of Vasilip, is a hypolipidemic agent obtained synthetically from the fermentation product of Aspergillus terreus.

After oral administration, simvastatin, which belongs to inactive lactones, undergoes hydrolysis in the liver, with the formation of the corresponding form of β-hydroxy acid of the substance. It is the main metabolite and has a high inhibitory activity against HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase, an enzyme that catalyzes the biological synthesis (the initial and most significant stage) of cholesterol.

The effectiveness of simvastatin in reducing the concentration of total cholesterol (total cholesterol) in the blood plasma, LDL cholesterol (low density lipoprotein cholesterol), TG (triglycerides) and VLDL cholesterol (very low density lipoprotein cholesterol), as well as increasing the concentration of HDL cholesterol (high lipoprotein cholesterol) has been confirmed. density) in blood plasma in patients with heterozygous familial / nonfamilial hypercholesterolemia or mixed hyperlipidemia in cases where an increased plasma concentration of cholesterol in the blood is a risk factor and the appointment of one diet is not sufficient A noticeable therapeutic effect is observed within 14 days of taking simvastatin, the maximum - within 4-6 weeks from the start of use. With continued therapy, the effect persists. The plasma concentration of cholesterol after stopping the intake of simvastatin in the blood returns to the initial value, which was observed before the start of treatment.

The active metabolite of simvastatin is a specific inhibitor of HMG-CoA reductase (an enzyme that catalyzes the formation of mevalonate from HMG-CoA). However, the intake of therapeutic doses of the substance does not lead to complete inhibition of HMG-CoA reductase, due to which the production of a biologically necessary amount of mevalonate is preserved. It is believed that the use of Vasilip should not cause the accumulation of potentially toxic sterols in the body, since the conversion of HMG-CoA to mevalonate is an early stage in the biological synthesis of CS. In addition, there is a rapid reverse metabolism of HMG-CoA to acetyl-CoA, which is involved in many biosynthetic processes in the body.

CS is a precursor of all steroid hormones, while the clinical effect of simvastatin on steroidogenesis is not observed. Since Vasilip does not lead to an increase in the lithogenicity of bile, its effect on an increase in the incidence of gallstone disease is unlikely.

Simvastatin helps to reduce both elevated and normal concentrations of LDL cholesterol in blood plasma. LDL is formed from VLDL (very low density lipoprotein). LDL catabolism is mediated primarily by the high affinity LDL receptor. The mechanism of a decrease in the concentration of LDL cholesterol in the blood plasma after taking simvastatin may be due to both a decrease in the plasma concentration of VLDL cholesterol in the blood and the activation of LDL receptors. Due to this, a decrease in the formation and an increase in the catabolism of LDL cholesterol is noted. Simvastatin therapy also significantly decreases the plasma concentration of apolipoprotein B (apo B) in the blood. Since each LDL particle contains one apo B molecule, and small amounts of apo B are found in other lipoproteins, it can be assumed that simvastatin, in addition,which causes the loss of cholesterol in LDL particles, helps to reduce the plasma concentration of circulating LDL particles in the blood.

Simvastatin also increases the concentration of HDL cholesterol and reduces the concentration of triglycerides in the blood plasma. As a result, the ratio of LDL cholesterol / HDL cholesterol and total cholesterol / HDL cholesterol decreases.

With ischemic heart disease (coronary artery disease) and an initial total cholesterol concentration of 212-309 mg / dL (from 5.5 to 8 mmol / L), simvastatin helps to reduce the risk of overall mortality, mortality from coronary heart disease, and the incidence of nonfatal confirmed myocardial infarctions. Also, the substance reduces the likelihood of the need for surgical interventions to restore coronary blood flow (for example, coronary artery bypass grafting or percutaneous transluminal coronary angioplasty). Against the background of diabetes mellitus, the likelihood of major coronary complications decreases. Moreover, during therapy with simvastatin, the risk of fatal / non-fatal disorders of cerebral circulation (including strokes and transient cerebrovascular accidents) is significantly reduced.

There is evidence of the efficacy of simvastatin in patients with / without hyperlipidemia, who are at high risk of developing coronary artery disease due to concomitant diabetes mellitus, a history of stroke and other vascular diseases.

When using Vasilip in a daily dose of 40 mg, overall mortality, the risk of death associated with coronary heart disease, the risk of major coronary complications (including nonfatal myocardial infarction or death associated with coronary heart disease), the need for surgical interventions to restore coronary blood flow (including coronary artery bypass grafting and percutaneous transluminal angioplasty), as well as peripheral blood flow and other types of non-coronary revascularization, the risk of stroke, the frequency of hospitalization for heart failure.

The likelihood of major vascular / coronary complications decreases in patients with / without coronary artery disease, including patients with peripheral vascular disease, diabetes mellitus, or cerebrovascular pathologies. In diabetes mellitus, Vasilip helps to reduce the risk of serious vascular complications, including the need for surgical interventions for amputation of the lower extremities, restoration of peripheral blood flow, and the occurrence of trophic ulcers.

According to coronary angiography, therapy with simvastatin leads to a slowdown in the progression of coronary atherosclerosis and the appearance of both new areas of atherosclerosis and new total occlusions, while patients receiving standard therapy showed a steady progression of atherosclerotic lesions of the coronary arteries.

Pharmacokinetics

Simvastatin is an inactive lactone. The substance is rapidly hydrolyzed, while it is converted into β-hydroxy acid simvastatin (L-654.969), which is a potent inhibitor of HMG-CoA reductase. The main metabolites of simvastatin in blood plasma are β-hydroxyacid of simvastatin (L-654.969) and its 6'-exomethylene, 6'-hydroxy and 6'-hydroxymethyl derivatives.

The criterion for the quantitative assessment of all pharmacokinetic studies of β-hydroxy acid metabolites (active inhibitors) and active / latent inhibitors (all inhibitors) that are formed as a result of hydrolysis is inhibition of HMG-CoA reductase. When taking simvastatin orally, both types of metabolites are determined in the blood plasma.

Hydrolysis of simvastatin occurs predominantly during the primary passage through the liver, therefore, there is a low plasma concentration of unchanged simvastatin in human blood (<5% of the dose taken). C _max (maximum concentration of the substance) of simvastatin metabolites in plasma achieved 1.3-2.4 hours after oral administration of a single dose. Maximum plasma concentration of total radioactivity (¹⁴ C labeled simvastatin + ¹⁴With labeled metabolites of simvastatin) is achieved in 4 hours. Then, within 12 hours, it rapidly decreases to about 10% of the maximum value. Despite the fact that the range of recommended therapeutic doses of simvastatin is from 5 to 80 mg per day, there is a preservation of the linear nature of the AUC profile (area under the concentration-time curve) of active metabolites in the general blood flow with an increase in the dose to 120 mg.

Approximately 85% of the accepted dose of simvastatin is absorbed. Eating (as part of the standard hypocholesterol diet) immediately after taking simvastatin has no effect on the pharmacokinetic profile of the drug.

Higher concentrations of simvastatin are determined in the liver (in comparison with other tissues).

The concentration in the systemic circulation of the active metabolite of simvastatin L-654.969 is <5% of the oral dose, 95% of this volume is in a state associated with blood plasma proteins.

The low concentration of simvastatin in the general circulation is the result of active metabolism in the liver (> 60% in men).

The possibility of penetration of the substance through the blood-brain and blood-placental barriers has not been studied.

Simvastatin during the initial passage through the liver is metabolized, the subsequent excretion of the substance and its metabolites occurs with bile.

When taking 100 mg of simvastatin ¹⁴ C, the labeled substance accumulates in the blood plasma, as well as in feces (about 60%) and urine (about 13%). In the feces, labeled simvastatin is represented by the products of simvastatin metabolism, which were excreted in the bile, and unabsorbed labeled simvastatin. Less than 0.5% of the taken dose of the labeled substance is found in the urine as active metabolites of the substance. In blood plasma, 14% and 28% of AUC are due to active inhibitors and all inhibitors of HMG-CoA reductase, respectively. This indicates that predominantly the metabolic products of simvastatin are inactive or weak inhibitors of HMG-CoA reductase.

There is no significant deviation in the linearity of AUC in the total blood flow with increasing dose in the range of 5–120 mg. With single and multiple oral administration of simvastatin, pharmacokinetic parameters demonstrated the absence of accumulation of the substance in tissues in the case of repeated use.

In severe renal failure (in patients with creatinine clearance <30 ml / min), the total plasma concentration of HMG-CoA reductase inhibitors in the blood after taking a single oral dose of the corresponding HMG-CoA reductase inhibitor (statin) exceeds that in healthy volunteers by approximately two times.

Therapy with simvastatin at a dose of 80 mg (maximum dose) in healthy volunteers did not affect the metabolism of midazolam and erythromycin, which are substrates of the CYP3A4 isoenzyme. This means that the substance is not an inhibitor of the CYP3A4 isoenzyme, and suggests that oral administration of simvastatin does not affect the plasma concentration in the blood of drugs metabolized by the CYP3A4 isoenzyme.

It was found that cyclosporine increases the AUC of HMG-CoA reductase inhibitors, while the mechanism of drug interaction is not fully understood. Presumably, the increase in the AUC of simvastatin is associated with inhibition of the CYP3A4 isoenzyme and / or the transport protein OATP1B1.

When combined therapy with diltiazem, an increase in the AUC of β-hydroxy acid of simvastatin is observed approximately 2.7 times, which is presumably due to inhibition of the CYP3A4 isoenzyme. When combined with amlodipine, the AUC of β-hydroxy acid of simvastatin increases 1.6 times.

In the case of the simultaneous use of 2000 mg (single dose) of slow-release nicotinic acid and 20 mg of simvastatin, there is a slight increase in C _{max of} β-hydroxy acid of simvastatin in blood plasma and AUC of simvastatin and β-hydroxy acid of simvastatin.

The specific pathways of metabolism in the liver of fusidic acid are unknown; there is an assumption about the presence of an interaction between fusidic acid and statins, which are metabolized by the isoenzyme CYP3A4.

The likelihood of myopathy with an increase in the concentration of HMG-CoA reductase inhibitors in blood plasma increases. Potent inhibitors of the isoenzyme CYP3A4 can lead to an increase in the concentration of HMG-CoA reductase inhibitors and the risk of myopathy.

Indications for use

Ischemic heart disease or high risk of its development

At a high risk of developing coronary artery disease with / without hyperlipidemia (for example, in patients with diabetes mellitus, stroke or other cerebrovascular diseases in history, coronary artery disease or a predisposition to its development, peripheral vascular disease)

• reducing the risk of overall mortality due to a decrease in mortality due to coronary heart disease;
• reducing the likelihood of serious coronary and vascular complications: coronary death, non-fatal myocardial infarction, revascularization procedure, stroke;
• reducing the risk of the need for surgical interventions for the restoration of coronary blood flow (coronary artery bypass grafting and percutaneous transluminal coronary angioplasty);
• reducing the risk of the need for surgical interventions to restore peripheral blood flow and other types of non-coronary revascularization;
• a decrease in the likelihood of hospitalization due to angina attacks.

Hyperlipidemia

Vasilip is prescribed as an adjunct to the diet in cases where the use of diet alone and other non-drug methods of therapy in patients with primary or mixed hypercholesterolemia (according to Fredrickson's classification - with type IIa and IIb hyperlipidemia) is not enough to achieve the following goals:

• a decrease in the increased plasma concentration of total cholesterol, LDL cholesterol, triglycerides, apolipoprotein B (apo B) in the blood;
• decrease in the ratio of LDL cholesterol / HDL cholesterol and total cholesterol / HDL cholesterol in blood plasma;
• an increase in the plasma concentration of HDL cholesterol in the blood.

Also, the use of Vasilip is indicated in the following cases:

• hypertriglyceridemia (according to Fredrickson's classification - type IV hyperlipidemia);
• primary dysbetalipoproteinemia (according to Fredrickson's classification - type III hyperlipidemia);
• homozygous familial hypercholesterolemia: to reduce the increased concentration of TC, LDL cholesterol and apo B (as an addition to diet and other methods of therapy).

Heterozygous familial hypercholesterolemia in children and adolescents

The use of Vasilip is indicated in order to reduce the increased concentration of total cholesterol, LDL cholesterol, TG, apo B in the blood plasma in young men 10-17 years old and girls of the same age [but not earlier than one year after menarche (first menstrual bleeding)] with heterozygous familial hypercholesterolemia (in combination with diet).

Contraindications

Absolute:

• liver disease in the active phase, or a persistent increase in the activity of hepatic transaminases in blood plasma of an unclear etiology;
• lactase deficiency, lactose intolerance or glucose-galactose malabsorption syndrome;
• combination therapy with gemfibrozil, danazol, or cyclosporine;
• combined use with powerful inhibitors of the CYP3A4 isoenzyme (drugs such as itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone and drugs containing cobicistat)
• pregnancy, as well as use in women planning pregnancy and women with preserved reproductive potential who do not use reliable methods of contraception;
• lactation period;
• age up to 18 years (except for children 10–17 years old with heterozygous familial hypercholesterolemia);
• individual intolerance to the components of Vasilip, as well as other statin drugs in the anamnesis.

Relative (Vasilip is prescribed under medical supervision):

• condition after undergoing rhabdomyolysis during therapy with Vasilip with a complicated history (impaired renal function, usually associated with diabetes mellitus) - more careful medical supervision is required; before performing major surgical interventions, as well as in the postoperative period, the use of the drug should be temporarily discontinued;
• a steady increase in the activity of serum transaminases - if the upper limit of the norm is exceeded three times, Vasilip must be canceled;
• severe renal failure (in patients with creatinine clearance 10 mg per day; if necessary, therapy is prescribed with caution;
• alcohol abuse before starting therapy;
• combined use with fibrates (with the exception of fenofibrate or gemfibrozil), amiodarone, lomitapide, slow calcium channel blockers (verapamil, amlodipine or diltiazem), moderate inhibitors of the CYP3A4 isoenzyme (dronedarone, ranolazine), fusicidic acid (niacinic acid in less 1000 mg), colchicine, inhibitors of the transport protein OATP1B1 - associated with an increase in the likelihood of rhabdomyolysis and myopathy;
• age from 65 years.

Vasilip, instructions for use: method and dosage

Vasilip tablets are taken orally, 1 time per day, in the evening. The recommended daily dosage ranges from 5 mg to 80 mg.

Most often, the drug is prescribed at an initial dose of 10 mg. Dosage changes must be made at intervals of at least 4 weeks. The maximum daily dose (80 mg) is recommended only for patients with severe hypercholesterolemia or a high risk of developing cardiovascular complications. The duration of taking Vasilip is determined individually by the attending physician.

With hypercholesterolemia:

Throughout the entire period of therapy, the patient should follow a standard hypocholesterol diet. The recommended starting dosage is 10 mg. In order to more pronounced lowering the level of LDL-C (more than 45%), taking Vasilip can be started with 20-40 mg once a day, in the evening.

Patients with homozygous hereditary hypercholesterolemia are recommended to take 40 mg once a day, in the evening. It is possible to use in 3 doses - in the morning and in the afternoon, 20 mg and 40 mg in the evening. For such patients, Vasilip is recommended to be taken in combination with other lipid-lowering therapy (for example, LDL apheresis).

In the prevention of cardiovascular diseases:

With a high risk of developing coronary heart disease (with or without hyperlipidemia), 20-40 mg of Vasilip is prescribed per day. The initial dose is 20 mg, the dose should be increased with an interval of at least 4 weeks. The maximum daily dose is 40 mg. When the content of LDL is less than 75 mg / dL (1.94 mmol / L), the content of total Xc is less than 140 mg / dL (3.6 mmol / L), the dosage of the drug should be reduced.

Concomitant therapy:

Vasilip is effective in monotherapy or concurrently with bile acid sequestrants (eg, colestipol and cholestyramine). In patients receiving treatment with gemfibrozil, cyclosporine, other fibrates or nicotinic acid (more than 1 g per day), it is recommended to start therapy with 5 mg per day, the maximum daily dose is 10 mg. In such situations, further dose increases are not recommended.

In patients receiving concurrently verapamil or amiodarone, the daily dose of Vasilip should not exceed 20 mg.

In patients with severe renal failure (CC less than 30 ml / min), the recommended daily dose of Vasilip should not exceed 10 mg. If it is necessary to increase the dose, close medical supervision is required.

Patients with moderate renal insufficiency and the elderly do not need dose adjustment.

Side effects

When using Vasilip, side effects rarely develop:

• From the digestive system: flatulence, constipation, dyspepsia, nausea, vomiting, abdominal pain, diarrhea, jaundice, pancreatitis, hepatitis, increased ALP activity, hepatic transaminases, creatine phosphokinase;
• From the musculoskeletal system: myopathy, rhabdomyolysis, myalgia, muscle cramps;
• From the sensory organs, central nervous system and peripheral nervous system: dizziness, headache, paresthesia, blurred vision, peripheral neuropathy, insomnia, convulsions, asthenia, taste disturbance;
• On the part of the skin: alopecia, skin rash, itching;
• Immune system and allergic reactions: extensive hypersensitivity syndrome - polymyalgia rheumatica, angioedema, dermatomyositis, vasculitis, thrombocytopenia, lupus-like syndrome, eosinophilia, arthritis, increased ESR, arthralgia, photosensitivity, fever, dizziness and urticaria, skin rash faces;
• Other: anemia, acute renal failure (due to rhabdomyolysis), palpitations, decreased potency.

Overdose

There are reports of several cases of overdose, it was reported that the maximum dose of simvastatin was taken, which is 3600 mg. The consequences of an overdose were not identified in any patient.

Therapy: supportive and symptomatic treatment.

special instructions

For women of reproductive age, when using Vasilip, it is necessary to use reliable contraception.

With an increase in the level of Xc in patients with reduced thyroid function (hypothyroidism) or in the presence of certain kidney diseases (nephrotic syndrome), the underlying disease should be initially treated.

Patients with severe renal failure, therapy should be carried out under the control of renal function.

Before starting treatment or when increasing the dose of Vasilip, the patient should be informed about the risk of myopathy and the need for immediate medical attention if unexplained pain, tension or weakness in the muscles appears, especially at the same time as fever or general weakness. Before starting therapy, the initial CPK level should be determined for alcohol abuse, the elderly, as well as patients with:

• Kidney damage;
• Hereditary muscle diseases;
• Decompensated hypothyroidism;
• A history of muscle toxicity with fibrates or statins.

Before and during therapy, the patient should follow a cholesterol-free diet.

If muscle pain, cramps, or weakness appear during drug therapy, the CPK level should be determined. The criterion for discontinuing Vasilip is an increase in the content of CPK in the blood serum more than 5 times relative to VGN. If you suspect the development of myopathy (regardless of the cause), treatment should be discontinued.

The simultaneous use of simvastatin and gemfibrozil is possible only in cases where the intended benefit of treatment significantly outweighs the potential risk of such a combination.

The drug can cause a slight and clinically insignificant increase in the activity of liver enzymes in the blood serum. Usually, after discontinuation of Vasilip, transaminase levels slowly decrease to the initial value. Nevertheless, before starting treatment and in the future, it is necessary to conduct a study of liver function (during the first 3 months, monitor the activity of hepatic transaminases every 6 weeks, then every 2 months for the remaining first year, then once every 6 months). Before increasing the dose to 80 mg, it is imperative to monitor liver function, then examinations are performed periodically. The drug therapy is discontinued with a persistent 3-fold increase in the activity of ACT and / or ALT in serum relative to VGN.

Vasilip is prescribed with caution in patients with alcohol abuse, as well as with a history of liver disease.

Influence on the ability to drive vehicles and complex mechanisms

There have been isolated cases of dizziness when using Vasilip, which should be taken into account when driving a car.

Application during pregnancy and lactation

Vasilip is not prescribed during pregnancy / lactation.

When pregnancy occurs, taking simvastatin should be stopped immediately. For women of childbearing age, Vasilip can be prescribed only in cases where the likelihood of pregnancy is very small. Drug therapy during pregnancy can lead to a decrease in the concentration of mevalonate (a precursor in cholesterol biosynthesis) in the fetus. Atherosclerosis is considered a chronic disease, and usually withdrawal of lipid-lowering drugs during pregnancy has little effect on the long-term risks associated with primary hypercholesterolemia. In this regard, simvastatin should not be prescribed to women who are pregnant, want to become pregnant, or suspect that they are pregnant. Vasilip therapy should be suspended for the entire period of pregnancy or until pregnancy is diagnosed, and the woman herself should be warned of the existing danger to the fetus.

There is no information confirming or refuting the excretion of simvastatin and its metabolites in breast milk.

Pediatric use

For patients under 18 years of age, Vasilip is not prescribed, except for use in heterozygous familial hypercholesterolemia in children 10–17 years old.

With impaired renal function

In severe renal failure (in patients with creatinine clearance of 10 mg per day, if necessary, therapy is prescribed with caution.

For violations of liver function

Vasilip is contraindicated for use in liver diseases in the active phase or with a persistent increase in the activity of hepatic transaminases in blood plasma of unclear etiology.

Use in the elderly

Elderly patients, Vasilip should be prescribed under medical supervision.

Drug interactions

Contraindicated combinations:

• potent inhibitors of the isoenzyme CYP3A4 (itraconazole, telithromycin, ketoconazole, posaconazole, clarithromycin, voriconazole, erythromycin, HIV protease inhibitors, boceprevir, nefazodone, telaprevir, drugs containing cobicistat; associated with an increase in the risk of sympathetic excretion due to a decrease in mystvatine excretion due to a decrease in the occurrence of mystvate)
• gemfibrozil, danazol, or cyclosporin.

Other drug interactions:

• gemfibrozil and other fibrates (excluding fenofibrate), fusidic acid: increased likelihood of developing myopathy;
• amiodarone, lomitapide, slow calcium channel blockers (verapamil, diltiazem, or amlodipine), lipid-lowering nicotinic acid (at least 1000 mg per day): increased likelihood of myopathy / rhabdomyolysis;
• moderate inhibitors of the isoenzyme CYP3A4 (for example, dronedarone, ranolazine): an increase in the likelihood of developing myopathy, the dose of Vasilip may be reduced;
• inhibitors of the transport protein OATP1B1: an increase in the plasma concentration of the hydroxy acid of simvastatin and the likelihood of developing myopathy;
• colchicine (in patients with renal failure): increased risk of myopathy and rhabdomyolysis; combined use requires careful monitoring of the patient's condition;
• indirect anticoagulants (coumarin derivatives): an increase in prothrombin time, defined as MHO (international normalized ratio); the value of the indicator is controlled before the start of therapy with simvastatin, then in the initial period of treatment it is determined quite often, which makes it possible to exclude significant changes in MHO. After a stable indicator of prothrombin time is reached, its further determination should be carried out with interruptions recommended for monitoring patients receiving anticoagulant therapy. In cases of changing the dose of simvastatin or after its cancellation, regular measurement of this indicator is also recommended. In patients who did not take anticoagulants, simvastatin therapy was not associated with bleeding or changes in prothrombin time;
• grapefruit juice (in large volumes): increased plasma activity of HMG-CoA reductase inhibitors.

Analogs

The analogues of Vasilip are: Zokor, Zokor Forte, Simvor, Simvakard, Simvastol, Simlo, Simvastatin Zentiva, SimvaGEKSAL, Zovatin, Levomir, Simvalimit, Aktalipid, Sincard, Aterostat, Zorstat, Simvakol, Simplakor, Simvastatin, Simvastatin Chaykapharma, Simvastatin-SZ, Simvastatin Alkaloid, Ovenkor, Simvastatin Pfizer.

Terms and conditions of storage

Keep out of reach of children at temperatures up to 30 ° C.

The shelf life is 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Vasilip

According to reviews, Vasilip effectively reduces blood cholesterol levels. Also note the duration of its action. Some patients indicate the development of adverse reactions. The cost is assessed as affordable, less often as high.

The price of Vasilip in pharmacies

The approximate price for Vasilip is: 10 mg tablets - 139-145 rubles. (14 pcs in the package) or 260-319 rubles. (28 pcs in the package), 20 mg each - 219–258 rubles. (14 pcs in the package) or 363-438 rubles. (in the package 28 pcs.), 40 mg - 551–652 rubles. (28 pcs in the package).

Vasilip: prices in online pharmacies

Drug name Price Pharmacy

Vasilip 10 mg film-coated tablets 28 pcs. RUB 128 Buy

Vasilip 20 mg film-coated tablets 28 pcs. 201 RUB Buy

Vasilip tablets p.o. 20mg 28 pcs. 448 r Buy

Vasilip 40 mg film-coated tablets 28 pcs. 760 RUB Buy

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!